Teclistamab in Previously Treated AL Amyloidosis

Prior treatment

• Previous anti-BCMA targeted therapy

Other illness

• Co-morbidity of uncontrolled infection
• Co-morbidity of other active malignancy
• Hepatitis B virus (HBV)-DNA \> 1000 copies/mL
• Seropositive for hepatitis C (except in the setting of a sustained virologic response)

Lab values

• Neutrophil \<1×10E9/L, hemoglobin \< 8g/dL, or platelet \< 75×10E9/L.
• Severely compromised hepatic or renal function: alanine transaminase (ALT) or aspertate aminotransferase (AST) \> 5 × upper limit of normal (ULN), total bilirubin \> 2 × ULN, eGFR \< 20 mL/min, or receiving renal replacement therapy

Other

• Co-diagnosis of multiple myeloma or waldenstrom macroglobulinemia
• Co-morbidity of grade 2 Mobitz II or grade 3 atrioventricular block (expect for those with implanted pacemaker)
• Co-morbidity of sustained or recurrent nonsustained ventricular tachycardia
• Seropositive for human immunodeficiency virus

• Biopsy confirmed AL amyloidosis
• Patients must have received at least one line of treatment, including daratumumab and bortezomib
• Relapse from previous treatment, or less than partial response after two cycles of treatment/less than very good partial response after three cycles of treatment
• dFLC \> 50mg/L